BSE · 531599 · Pharmaceuticals
FDC Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹655 Cr with net profit ₹132 Cr — a 20.15% net margin, versus 12.32% the period before.
Shareholding
As of 2026-06-30
- Promoter69.66%
- Public22.63%
- FII1.4%
- DII6.31%
55,045 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.68× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #35 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,48,028 Cr | 35.46 | 5.36 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,13,227 Cr | 23.19 | 4.18 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,11,186 Cr | 31.07 | 3.23 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,258 Cr | 96.25 | 19.86 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹98,075 Cr | 30.44 | 2.58 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹97,239 Cr | 25.72 | 2.57 | 9.25% | 10.7% |
| Lupin Limited | ₹95,939 Cr | 16.11 | 4.27 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹95,000 Cr | 44.53 | 5.83 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,185 Cr | 21.85 | 6.49 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹63,949 Cr | 28.06 | 4.63 | 16.66% | 14.31% |
| FDC Ltd.(this company) | ₹5,753 Cr | 18.69 | 2.31 | 11.32% | 13.36% |
AI analysis
AI-generated · google/gemini-2.5-flashFDC Ltd. (531599), operating in the Pharmaceuticals sector, has a market capitalization of Rs 6688 Cr. The company reported a revenue growth of 8.5% and a profit margin of 12.96%. Its book value stands at Rs 152.64, with earnings per share (EPS) of Rs 18.24. The return on equity (ROE) is 11.32% and return on capital employed (ROCE) is 15.18%. The debt-to-equity ratio is 0.01, and it offers a dividend yield of 1.21%.
Positives
- +The company has a low debt-to-equity ratio of 0.01, indicating conservative financial management.
- +Promoter holding is substantial at 69.6581% as of June 2026.
- +There are no promoter shares pledged, with promoter pledge recorded at 0%.
Negatives
- −Quarterly net profit for December 2025 decreased to Rs 28.3 Cr from Rs 121.35 Cr in June 2025, despite similar revenues of Rs 464.71 Cr and Rs 648.41 Cr respectively.
- −No annual EPS figures for the provided periods.
Financial Performance
FDC Ltd. recorded revenue growth of 8.5%. The company's net profit in March 2026 was Rs 103.4 Cr on a revenue of Rs 584.79 Cr. In the December 2025 quarter, net profit was Rs 28.3 Cr from a revenue of Rs 464.71 Cr. For June 2025, net profit reached Rs 121.35 Cr with revenue at Rs 648.41 Cr.
Profitability & Returns
The company’s profit margin is 12.96%. It has an earnings per share (EPS) of Rs 18.24. Return on equity (ROE) is 11.32%, and return on capital employed (ROCE) stands at 15.18%. The Price-to-Earnings (PE) ratio is 22.52.
Balance Sheet
FDC Ltd. maintains a low debt-to-equity ratio of 0.01. The book value per share is Rs 152.64. The company's stock traded between a 52-week high of Rs 528.3 and a 52-week low of Rs 314.75.
Ownership & Pledges
Total institutional holding is 7.7132%. There are no promoter shares pledged, with promoter pledge at 0%.
Data as of — price: 2026-09-17 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.